KOL Perception in MASH
KOL Perception Assessment in MASH Management and Emerging Treatment Landscape in the US & EU
This primary MASH research study captures expert perspectives from hepatologists, gastroenterologists, endocrinologists, academic researchers, and MASH specialists across the United States and Europe. The survey focuses on disease awareness, diagnosis, unmet needs, screening practices, and the adoption outlook for emerging MASH therapies.
25 MASH KOLs
US & Europe
2–3 Weeks Fieldwork
15–20 Min Interviews
25
Total MASH KOLs surveyed
13
US respondents
12
EU respondents
7
Average survey questions
Study Overview
KOL Perception in MASH: Overview & Objectives
This study evaluates MASH KOL perceptions on disease awareness, diagnosis, unmet needs, screening practices, and the adoption of emerging therapies. It also captures expert expectations for future MASH management strategies across the United States and Europe.
The primary research objective is to understand expert perspectives on the current MASH treatment landscape, identify key barriers to diagnosis and treatment, assess confidence in available diagnostic tools, and evaluate expectations for future therapies and patient management.
| Parameter | Details |
|---|---|
| Study Title | KOL Perception Assessment in MASH Management and Emerging Treatment Landscape |
| Study Objective | Evaluate MASH KOL perceptions on awareness, diagnosis, unmet needs, screening, and emerging therapies |
| Methodology | Quantitative online survey |
| Respondent Type | Hepatologists, gastroenterologists, endocrinologists, academic researchers, MASH specialists |
| Geography | United States and Europe |
| Total Sample Size | 25 KOLs |
| US Respondents | 13 |
| EU Respondents | 12 |
| Fieldwork Duration | 2–3 weeks |
| Interview Length | 15–20 minutes |
| Survey Type | Structured questionnaire with closed-ended responses |
Respondent Profile
MASH KOL Specialty Breakdown
| Specialty | Number of Respondents | % |
|---|---|---|
| Hepatologists | 10 | 40% |
| Gastroenterologists | 6 | 24% |
| Endocrinologists | 4 | 16% |
| Academic Researchers | 3 | 12% |
| MASH Specialists | 2 | 8% |
| Total | 25 | 100% |
Survey Results
MASH KOL Survey Findings
Question 01
How would you rate the current level of awareness of MASH among non-specialist physicians?
Very High
4%
High
20%
Moderate
44%
Low
28%
Very Low
4%
- Most KOLs (76%) perceive awareness among non-specialist physicians as moderate or lower, highlighting ongoing education needs.
- EU respondents were slightly more critical than US respondents regarding awareness levels.
Question 02
What is the most significant unmet need in MASH management today?
Earlier Diagnosis
36%
Better Non-invasive Biomarkers
36%
Effective Drug Therapies
20%
Improved Patient Adherence
8%
- Earlier diagnosis and better non-invasive biomarkers account for 72% of responses, underscoring diagnostic challenges in MASH management.
Question 03
How confident are you in currently available non-invasive diagnostic tools?
Very Confident
4%
Confident
28%
Neutral
36%
Not Very Confident
28%
Not at All Confident
4%
- Only one-third of respondents expressed confidence in current non-invasive diagnostic tools, pointing to a clear need for innovation and validation.
Question 04
Which patient population should be prioritized for routine MASH screening?
Type 2 Diabetes
44%
Obesity
32%
Metabolic Syndrome
16%
General Population
8%
- Type 2 Diabetes patients are viewed as the highest-risk group for routine MASH screening, followed by those with obesity.
Question 05
How likely are emerging therapies to significantly change MASH management within the next 5 years?
Extremely Likely
36%
Very Likely
40%
Somewhat Likely
16%
Unlikely
8%
- Seventy-six percent believe emerging therapies will fundamentally improve MASH management over the next five years.
Question 06
Which factor will most influence adoption of newly approved MASH therapies?
Clinical Efficacy
40%
Safety Profile
24%
Reimbursement/Market Access
20%
Guideline Inclusion
8%
Ease of Administration
8%
- Clinical efficacy is the leading adoption driver for new MASH therapies, followed by safety and reimbursement considerations.
Question 07
What is the biggest barrier to achieving optimal MASH patient outcomes?
Late Diagnosis
40%
Limited Specialist Access
20%
Poor Patient Engagement
20%
Reimbursement Challenges
12%
Treatment Complexity
8%
- Late diagnosis is the leading barrier to optimal MASH outcomes, reinforcing diagnostic gaps across the disease pathway.
Overall Study Findings
Key MASH Study Takeaways
| Key Theme | Finding |
|---|---|
| Awareness | 76% perceive awareness among non-specialists as moderate-to-low |
| Diagnostic Challenges | 68% report limited confidence in current non-invasive tools |
| Top Unmet Need | Earlier diagnosis and improved biomarkers (72%) |
| Screening Focus | Type 2 Diabetes patients identified as highest priority |
| Future Outlook | 76% expect emerging MASH therapies to significantly impact treatment |
| Adoption Driver | Clinical efficacy is the most important factor |
| Outcome Barrier | Late diagnosis remains the leading challenge |
Regional Comparison
US vs EU KOL Perspectives
| Topic | US Perspective | EU Perspective |
|---|---|---|
| Disease Awareness | Slightly higher perceived awareness | Greater concern regarding under-recognition |
| Diagnostic Confidence | Similar to EU | Similar to US |
| Screening Practices | Strong emphasis on T2D screening | Strong emphasis on T2D screening |
| Therapy Adoption | Focus on efficacy and access | Focus on efficacy and reimbursement |
| Future Expectations | Highly optimistic | Highly optimistic |
